Fact-checked by Grok 2 weeks ago

Denervation

Denervation refers to the loss or interruption of supply to a , , or body part, which disrupts normal physiological functions and often leads to , , and in the affected area. This condition arises from diverse causes, including physical injury such as , disease processes like or disorders, chemical toxicity, or deliberate surgical or procedural interventions to alleviate pain or treat specific pathologies. In muscles, denervation immediately impairs contractility and elasticity, triggering rapid structural changes like fiber shrinkage and replacement by fat, while in , it results in and delayed repair. The physiological consequences of denervation are profound and multifaceted, particularly in , where the loss of motor innervation severs stable interactions at the , essential for maintaining muscle integrity. This initiates a cascade of events, including activation of atrophy-related signaling pathways, disassembly, and metabolic shifts—such as in slow-twitch fibers and heightened in fast-twitch fibers over time—ultimately leading to significant muscle if untreated. Denervation also features prominently in experimental models to study muscle , with research tracing back to early 20th-century investigations and expanding in recent decades to explore therapeutic interventions like electrical or pharmacological targeting of ligases and calpains. In clinical practice, denervation is both a pathological outcome and a ; for instance, renal denervation is a catheter-based approved by the U.S. in 2023, which ablates sympathetic nerves along the renal arteries to reduce in patients with resistant unresponsive to medications. This minimally invasive approach interrupts overactive neural signals contributing to , demonstrating sustained efficacy with minimal side effects in clinical trials, and was included in the 2025 ACC/AHA guidelines as a recommended treatment option for uncontrolled . Other applications include selective denervation for relief in joints like the , preserving motion while targeting afferent nerves. Overall, understanding denervation underscores the critical role of neural innervation in and informs strategies to mitigate its debilitating effects across , , and orthopedics.

Fundamentals

Definition

Denervation refers to the disruption or loss of nerve supply to an organ, muscle, or tissue, resulting in impaired innervation and subsequent functional deficits in the affected area. This process deprives the target tissue of neural communication, which is essential for maintaining normal physiological functions such as , , or autonomic . The core mechanisms of denervation involve the severance of , which triggers the degeneration of nerve terminals and initiates . In , the distal segment of the severed undergoes rapid disintegration and clearance by macrophages and Schwann cells, leading to the complete breakdown of the nerve fiber beyond the injury site. This axonal fragmentation disrupts the transmission of electrical impulses and trophic signals from the to the innervated . Denervation can be classified as complete, involving the total loss of supply to the affected , or partial, where only a portion of the innervating s is compromised, potentially resulting in heterogeneous functional impairments. Complete denervation typically leads to uniform and loss of excitability in the target , whereas partial denervation may preserve some residual depending on the extent of involvement. Examples of systems affected by denervation include , where it causes and due to the loss of motor innervation; viscera, such as the , leading to impaired from autonomic disruption; and sensory regions, resulting in numbness or altered from the interruption of afferent pathways.

Historical Background

The concept of denervation traces its roots to the mid-19th century, when neurophysiologist Volney Waller conducted pioneering experiments on . In 1850, Waller severed the glossopharyngeal and hypoglossal nerves in frogs and observed the subsequent degeneration of the distal nerve segments, a process now known as , which laid the foundational understanding of axonal breakdown following denervation. These observations, detailed in his seminal paper, highlighted the structural changes in nerve fibers after transection and became central to subsequent studies on nerve degeneration and regeneration. By the mid-20th century, surgical interventions emerged as practical applications of denervation principles, particularly for managing . In 1953, surgeon Reginald H. Smithwick reported on the outcomes of splanchnicectomy, a procedure involving the resection of to interrupt sympathetic innervation, in 1,266 patients with ; this marked one of the earliest widespread denervation techniques, demonstrating significant reductions in many cases despite operative risks. Smithwick's work built on earlier sympathectomy efforts from the and , refining the approach to target thoracolumbar sympathetic chains more selectively. Advancements in minimally invasive methods accelerated in the with the development of radiofrequency neurotomy. In 1971, C. Norman Shealy introduced radiofrequency denervation of spinal s as a treatment for chronic back and , using electrode-generated heat to ablate sensory nerves while sparing motor function; this technique represented a shift from open to targeted lesioning. Shealy's innovation, inspired by prior studies, established as a cornerstone for -related denervation procedures. Modern denervation procedures gained prominence with the advent of catheter-based renal sympathetic denervation for resistant . In 2009, Markus P. Schlaich, Murray Esler, and colleagues published the first report of percutaneous renal denervation using via the , showing sustained lowering in 45 patients over 12 months without major complications. Building on this, by 2025, the U.S. had approved multiple systems, including expansions for broader indications following pivotal trials. That year, the / guidelines incorporated renal denervation as a recommended adjunctive for uncontrolled despite optimal medical management. Concurrently, the issued a national coverage determination, enabling reimbursement for and ultrasound-based renal denervation in eligible patients.

Etiology

Traumatic Injuries

Traumatic injuries represent a primary of denervation, occurring when mechanical forces disrupt the continuity or function of peripheral s, leading to the loss of neural innervation to target tissues. These injuries are particularly prevalent in high-impact scenarios such as accidents, falls, and sports-related incidents, where direct or indirect forces compromise nerve integrity. Unlike pathological or iatrogenic causes, traumatic denervation arises acutely from external physical trauma, often affecting mixed motor and sensory nerves in the extremities. The classification of traumatic injuries, originally proposed by Herbert Seddon in , provides a framework for understanding the severity and prognosis of denervation. , the mildest form, involves a temporary conduction block due to focal demyelination or ischemia, with intact axons and endoneurial tubes, resulting in transient sensory or motor deficits without axonal disruption. features axonal disruption while preserving the surrounding sheaths, leading to distal to the injury site but potential for spontaneous regeneration. represents complete transection, with full disruption of all structural elements, necessitating surgical intervention for any hope of recovery. This system highlights how the degree of structural damage correlates with the extent of denervation. Common mechanisms of traumatic denervation include lacerations from like or knives, which sever s cleanly; crush injuries from compressive forces such as those in or machinery accidents, damaging axons through internal hemorrhage and ischemia; and stretch injuries, often seen in traction events like crashes or sports tackles, where excessive elongation (e.g., beyond 8% of length) impairs and fiber integrity. These mechanisms predominantly affect peripheral nerves due to their superficial and elongated anatomy, with the being especially vulnerable in upper extremity traumas. Incidence rates underscore the public health impact of traumatic denervation, with peripheral nerve injuries occurring in approximately 2-3% of cases overall, though injuries specifically affect 1-2% of multitrauma victims, particularly in high-velocity incidents like accidents. These figures are derived from large-scale epidemiological studies and highlight the higher risk in young males engaged in vehicular or recreational activities. The initial consequences of traumatic denervation manifest as immediate loss of sensory and motor function distal to the injury site, including numbness, , weakness, or in the affected distribution, depending on the involved. This functional deficit arises from the interruption of axonal conduction, with often preceding motor symptoms in partial injuries.

Pathological Disorders

Denervation in pathological disorders arises from diverse processes including neurodegenerative, inflammatory/autoimmune, and metabolic conditions that target neurons, myelin, or axons, leading to insidious loss of nerve-muscle connectivity distinct from acute trauma. In neurodegenerative conditions, such as (ALS), progressive degeneration of upper and lower motor neurons results in widespread denervation of fibers, with compensatory reinnervation via collateral sprouting initially mitigating but ultimately failing to offset the loss. By the time of , electromyographic studies reveal denervation activity in approximately 72% of weak muscles in ALS patients, reflecting substantial involvement that correlates with disease severity. Similarly, , affecting 25-40% of poliomyelitis survivors, features ongoing cycles of denervation and reinnervation decades after initial infection, driven by the exhaustion of surviving motor neurons' sprouting capacity and leading to renewed and . Metabolic disorders, particularly , represent another major cause, where chronic induces , microvascular damage, and axonal degeneration, resulting in distal symmetric and denervation primarily affecting sensory and autonomic nerves. This condition develops in approximately 50% of patients with long-standing diabetes mellitus, leading to sensory loss, pain, and autonomic dysfunction, with showing reduced nerve conduction and denervation potentials in affected fibers. Inflammatory and autoimmune disorders further contribute to denervation through immune-mediated damage to peripheral nerves. Guillain-Barré syndrome (GBS), an acute polyradiculoneuropathy, primarily involves demyelination of peripheral nerves, which disrupts conduction and secondarily causes axonal degeneration and denervation, manifesting as rapid and . This process often results in conduction block as the dominant mechanism of acute paralysis, with variable degrees of axonal denervation contributing to prolonged recovery challenges. In contrast, (MS), a , induces denervation patterns that can be focal—corresponding to localized plaques causing segmental axonal loss—or diffuse, arising from widespread injury in normal-appearing and leading to secondary in peripheral projections. These patterns highlight the disease-specific variability in denervation extent and distribution, influencing clinical progression and therapeutic targeting.

Iatrogenic Causes

Iatrogenic denervation refers to the loss of supply resulting from medical interventions, either as an intended therapeutic outcome or as an unintended complication. These cases arise during surgical or procedural manipulations where nerves are directly or indirectly affected, leading to disruption of neural innervation to target tissues. Such denervation can manifest as , motor deficits, or autonomic dysfunction, depending on the nerve involved and the extent of damage. Surgical procedures often intentionally induce denervation to achieve therapeutic goals, such as in sympathectomy for severe . In this , the sympathetic chain is severed or clipped to interrupt excessive sympathetic activity, resulting in targeted denervation of sweat glands in the palms, axillae, or face. For instance, at levels T2-T4 effectively reduces palmar sweating but may lead to compensatory elsewhere due to the denervation's impact on autonomic balance. Similarly, resection is employed during tumor removal when neoplasms infiltrate neural structures, necessitating sacrifice of affected roots to ensure complete oncologic resection. In spinal foraminal nerve sheath tumors, for example, the involved root is often resected, causing localized denervation and potential motor or sensory deficits in the corresponding dermatome or . Procedural interventions like () provide another avenue for deliberate denervation in . uses heat generated by radio waves to ablate sensory nerves, such as those innervating facet joints in the spine, thereby blocking pain signal transmission for 6-24 months. This technique is particularly applied in low back or refractory to conservative treatments, where precise targeting minimizes broader neural disruption. Unintentional iatrogenic denervation, conversely, occurs as a complication in approximately 1-5% of spinal surgeries, often from direct trauma, retraction, or thermal injury during procedures like or fusion. These incidents can affect roots of the or peripheral nerves, leading to or neuropathy. Therapeutic denervation extends to other specialized applications, including denervation via for facet-mediated , which alleviates pain by disrupting nociceptive afferents without major motor impairment. Historical procedures like splanchnicectomy, involving denervation of visceral sympathetic nerves for chronic , represent early iatrogenic approaches now largely supplanted by less invasive methods. Overall, while iatrogenic denervation enables symptom control in select conditions, it carries risks of persistent deficits, underscoring the need for meticulous preoperative planning and intraoperative nerve monitoring.

Pathophysiology

Immediate Physiological Changes

Upon denervation, the distal segment of the severed undergoes , a process characterized by rapid fragmentation and disintegration of the axonal structure. This degeneration typically begins within 24-48 hours post-injury, with initial changes in intramembranous particle distribution observable in axons and Schwann cells as early as 12-24 hours, followed by detectable fragmentation by light microscopy at 36-44 hours in models. Schwann cells initiate breakdown and express cytokines such as TNFα and IL-1α within 5-6 hours, recruiting macrophages that peak in activity around 7 days to phagocytose debris, thereby clearing the distal segment by 12-14 days. In the neuronal cell body, denervation triggers chromatolysis, involving the dissolution and dispersal of Nissl bodies (rough endoplasmic reticulum) as a reactive response to axotomy. This change typically emerges 2-5 days after injury, with central chromatolysis—marked by cell body swelling, eccentric nuclear displacement, and reduced synthesis—peaking between 7 and 14 days, reflecting metabolic reprogramming to support potential regeneration. These alterations in the proximal stump prepare the for axonal regrowth but temporarily impair protein synthesis. Denervated target organs, particularly skeletal muscles, experience an immediate loss of neural trophic support, leading to membrane hyperexcitability and instability. Within hours to days, muscle fibers exhibit spontaneous and fibrillation potentials, which emerge 3-7 days post-denervation and peak at 7-10 days with amplitudes up to 451 μV in models, due to upregulated extrajunctional receptors and disrupted resting . This instability contributes to early , with muscle wet weight declining to 55-60% of contralateral controls within 2 weeks and type II fibers atrophying faster than type I. Systemically, denervation induces neuroplasticity in the central nervous system, including cortical reorganization as an adaptive response to sensory and motor input loss. In the somatosensory and motor cortices, immediate rearrangements occur within hours, involving expansion of adjacent representational areas and bilateral recruitment, driven by imbalances in excitatory/inhibitory neurotransmission and neurotrophic factors like BDNF; these changes evolve over the first 1-2 weeks before stabilizing. Such plasticity, while potentially compensatory, can lead to maladaptive remapping if prolonged. Overall, these immediate physiological changes—encompassing axonal degeneration, chromatolysis, muscle instability, and cortical reorganization—intensify and peak within the first 1-2 weeks, setting the stage for subsequent neural and responses without reinnervation.

Long-Term Tissue Effects

Denervation induces profound and progressive changes in , primarily manifesting as characterized by a substantial loss of muscle mass. In experimental models, denervated muscles can lose up to 50% of their cross-sectional area within the first three months, with further reductions leading to 50-70% overall mass loss by 3-6 months post-injury. This stems from disrupted neurotrophic support, resulting in and impaired protein synthesis, which progressively diminishes muscle fiber size and number. Functional impairments in denervated muscle include slowed speed and reduced generation, exacerbating the loss of contractile capacity. and relaxation phases become notably prolonged, with muscle conduction velocities dropping as low as 0.5 m/s in cases, compared to normal values exceeding 3 m/s. Tetanic , in particular, declines dramatically, often to less than 10% of baseline within weeks to months, reflecting the of fast-twitch fibers toward slower, less efficient phenotypes and eventual degeneration. In sensory tissues, long-term denervation leads to a spectrum of alterations, including numbness from sensory loss and or due to aberrant reinnervation or central sensitization in denervated dermatomes. emerges as a key pathological feature across affected tissues, with excessive deposition replacing functional , particularly in denervated muscle and , contributing to and impaired regeneration. Visceral organs exhibit denervation-dependent dysfunction, such as altered and ; for instance, in the , chronic denervation disrupts detrusor contractility, leading to underactivity with incomplete emptying or overactivity with urgency and incontinence due to patchy efferent loss. Without , complications like joint contractures arise from persistent and shortening, while irreversible dominates by 12-18 months, rendering tissues non-viable for effective reinnervation and perpetuating functional deficits.

Diagnosis

Clinical Presentation

Denervation manifests primarily through disruptions in motor, sensory, and autonomic functions, depending on the affected nerve fibers. Motor symptoms typically include immediate or in the denervated region due to loss of neural input to the . In the early stages, fasciculations—visible, spontaneous twitches of muscle fibers—may occur as a result of denervation-induced instability in motor units. Over time, these progress to chronic , with significant reduction in muscle bulk if reinnervation does not occur. Sensory symptoms arise from interruption of afferent nerve pathways, leading to numbness or loss of in the affected dermatomes or peripheral distribution. Paresthesias, such as tingling or "pins and needles" sensations, often precede complete sensory loss and may initially be distal before spreading proximally. Additionally, deep tendon reflexes are diminished or absent ( or areflexia) due to disruption of the reflex arc involving both sensory and motor components. Autonomic symptoms reflect damage to unmyelinated or small myelinated fibers, resulting in abnormalities such as altered sweating ( dysfunction), including anhidrosis or compensatory in adjacent areas. changes, like cool, pale, or shiny in the denervated territory, stem from impaired vascular tone regulation and may contribute to in more extensive involvement. The clinical course often begins with acute and sensory disturbances shortly after nerve disruption, evolving over weeks to months into persistent weakness, sensory deficits, and if untreated.

Imaging and Electrophysiological Tests

Electrophysiological tests, particularly (EMG) and nerve conduction studies (NCS), serve as primary objective tools for confirming denervation by assessing electrical activity in nerves and muscles. In EMG, denervation is indicated by the presence of spontaneous potentials such as fibrillation potentials and positive sharp waves, which arise from individual denervated muscle fibers firing repetitively in the absence of innervation. These potentials typically emerge 1-4 weeks following axonal injury, with fibrillation potentials detectable as early as days to weeks post-denervation and becoming more prominent over time. EMG demonstrates high sensitivity for detecting denervation after the onset of spontaneous activity around 2-3 weeks post-injury, making it a reliable marker for subacute phases. Nerve conduction studies complement EMG by evaluating nerve function through measurements of conduction velocity and amplitude. In axonal denervation, NCS often reveal reduced compound muscle action potential (CMAP) amplitudes due to loss of functioning axons, while conduction velocities remain relatively normal or only mildly reduced, distinguishing it from demyelinating neuropathies where velocity is more prominently slowed. These findings help localize the injury and quantify the extent of axonal loss, providing prognostic insights into potential recovery. Imaging modalities offer non-invasive visualization of structural and tissue changes associated with denervation, aiding in confirmation and characterization. (MRI) detects early nerve abnormalities such as swelling and increased T2-weighted signal intensity in affected nerves, reflecting and shortly after . In denervated muscles, MRI shows diffuse hyperintensity on fluid-sensitive sequences like short tau inversion recovery (STIR), corresponding to , which progresses to fatty infiltration and in chronic cases; this makes MRI particularly sensitive for identifying target muscle denervation compared to other techniques. Ultrasonography provides real-time, dynamic assessment of muscle and architecture, useful for bedside evaluation. It reveals increased muscle intensity and reduced thickness in denervated tissues due to replacement by fat and fibrous elements, allowing quantification of and without . High-resolution neuromuscular can also depict enlargement or discontinuity, enhancing its role in peripheral assessment. Advanced imaging techniques further refine denervation evaluation by targeting microstructural and metabolic alterations. Diffusion tensor imaging (DTI) with visualizes fiber tracts by exploiting water diffusion , enabling depiction of disrupted axonal pathways and assessment of regeneration potential in peripheral s. (), often using 18F-fluorodeoxyglucose (FDG), highlights increased metabolic activity in denervated muscles, where elevated standardized uptake values (SUVs) correlate with the severity of lesions due to inflammatory and reparative processes. These methods are especially valuable for complex cases, such as injuries, where conventional imaging may be inconclusive.

Management and Treatment

Reinnervation Approaches

Reinnervation approaches aim to restore nerve supply to denervated tissues through surgical, stimulatory, and regenerative strategies, particularly in peripheral nerve injuries where timely intervention can mitigate long-term muscle atrophy. Surgical techniques form the cornerstone of reinnervation, with nerve grafting involving the harvest and implantation of autologous nerve segments—such as sural or radial nerves—to bridge gaps in damaged nerves, facilitating axonal regrowth across the defect. In cases of proximal injuries like brachial plexus trauma, nerve transfers are preferred, where expendable donor nerves (e.g., intercostal or medial pectoral nerves) are redirected to reinnervate key motor branches, such as those to the biceps or deltoid, bypassing irreparable segments. Optimal timing for these procedures is within 6 months post-injury, ideally within 3 months, as delays beyond this window reduce the potential for effective axonal sprouting due to progressive target muscle degeneration. Electrical enhances reinnervation by promoting axonal and accelerating regeneration, typically applied intraoperatively or post-repair via brief (20-60 minute) low-intensity currents to the proximal to the repair site. This modality upregulates regeneration-associated genes and , leading to faster muscle reinnervation and improved functional outcomes in 20-30% of cases compared to repair alone, particularly when combined with . Regenerative therapies leverage cellular and biomaterial innovations to support nerve regrowth and preserve muscle integrity. therapies, including mesenchymal s derived from or , promote reinnervation by differentiating into Schwann-like cells, secreting , and modulating inflammation at the injury site. Myogenic cells, such as muscle-derived progenitor cells, facilitate muscle-nerve interfaces by enhancing reformation and reducing in denervated tissues. Recent 2025 advances include injectable dual-crosslinked hydrogels loaded with extracellular vesicles, which prevent by sustaining trophic support and promoting sustained nerve-muscle connectivity in models of denervation. Overall success rates for functional recovery in peripheral nerve injuries range from 50-70% when reinnervation is addressed early, with metrics like Medical Research Council grades M3-M4 (antigravity strength) achieved in a majority of surgically managed cases, though outcomes vary by injury severity and patient factors.

Symptomatic and Adjunctive Therapies

Symptomatic therapies for denervation primarily aim to alleviate secondary complications such as pain, muscle imbalances, and functional decline without attempting to restore neural connectivity. Pharmacological interventions include injections to manage that may arise in cases of incomplete or injuries, where excessive contributes to discomfort and reduced mobility. acts by inhibiting release at the , providing temporary relief from and improving passive . For , a common of denervation involving aberrant sensory signaling, analgesics such as gabapentinoids (e.g., ) or tricyclic antidepressants are employed to modulate pain pathways, with topical formulations showing efficacy in reducing and in chronic models. Multimodal analgesia, incorporating non- agents like acetaminophen and anti-inflammatory drugs, is recommended to minimize reliance while addressing persistent . Physical therapies focus on preserving musculoskeletal integrity and preventing progressive deterioration. Rehabilitation exercises, including stretching and strengthening protocols, are essential to counteract contractures by maintaining flexibility and promoting circulation in denervated limbs. Orthotic devices provide , stabilizing affected areas to facilitate ambulation and daily activities while protecting against further strain. These interventions help sustain residual function and reduce the risk of secondary deformities. Adjunctive approaches encompass emerging strategies to support tissue health amid denervation. is utilized to maintain muscle function, with low-frequency protocols demonstrating reductions in by stimulating contractions that mimic neural input and preserve . trials involving , such as ciliary neurotrophic factor (CNTF) delivered via autologous muscle stem cells, aim to enhance neuronal survival and limit degenerative changes in peripheral nerve injuries. Emerging 2024-2025 research on agents like has shown potential in counteracting muscle wasting in denervation models by activating Nrf2 pathways. Overall, these therapies can attenuate progression through consistent application, emphasizing multidisciplinary management to optimize .

Clinical Applications

Renal Denervation

Renal denervation (RDN) is a minimally invasive, catheter-based procedure designed to treat resistant hypertension by ablating the sympathetic nerves surrounding the renal arteries, thereby interrupting overactive neural signals that contribute to elevated blood pressure. The procedure typically involves accessing the renal arteries via the femoral or radial artery, followed by the application of radiofrequency energy or ultrasound to deliver targeted ablation in a circumferential pattern along the arterial walls, without requiring incisions or general anesthesia. This approach targets the renal sympathetic nervous system, which plays a key role in regulating blood pressure through vasoconstriction and sodium retention. The primary indication for RDN is treatment-resistant , defined as persistently elevated despite adherence to at least three antihypertensive medications of different classes, including a , with office systolic typically ≥140 mmHg confirmed by ambulatory monitoring. Clinical trials have demonstrated that RDN reduces office and ambulatory systolic by an average of 5-10 mmHg at 6-12 months post-procedure, with sustained effects observed up to 3 years in select cohorts, offering a device-based adjunct to for patients intolerant to or uncontrolled on medications. This lowering is attributed to the reduction in sympathetic outflow, as evidenced by meta-analyses of randomized sham-controlled trials showing consistent across diverse patient populations. As of 2025, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines recommend RDN as a third-line therapy option for adults with resistant hypertension (systolic blood pressure 140-180 mmHg and diastolic ≥90 mmHg) who remain uncontrolled on optimized medical regimens, marking its integration into standard clinical practice following robust evidence from pivotal trials. The U.S. Food and Drug Administration (FDA) has approved multiple RDN systems, with regulatory clearance extended to over 60 countries worldwide, facilitating broader global access to radiofrequency and ultrasound-based devices. Additionally, the Centers for Medicare & Medicaid Services (CMS) provides national coverage for RDN procedures in eligible patients with estimated glomerular filtration rate (eGFR) greater than 45 mL/min/1.73 m², aligning with device labeling to ensure safety in those without advanced kidney disease. Despite its favorable safety profile, RDN carries risks including renal arterial injury, such as or , occurring in less than 1% of cases based on procedural data from large registries and trials. Efficacy can vary due to anatomical heterogeneity in renal distribution and , with factors like depth and branching patterns influencing the completeness of and long-term response, underscoring the importance of operator experience and imaging guidance during the procedure. Overall, major adverse events are rare, with no significant impact on renal function reported in patients with preserved baseline health.

Other Therapeutic Denervations

Therapeutic denervations beyond renal applications primarily target sympathetic or sensory nerves to alleviate symptoms in cardiovascular, pulmonary, and musculoskeletal disorders. These procedures, often minimally invasive and guided by , aim to interrupt aberrant neural signaling contributing to disease progression or . Common modalities include , surgical sympathectomy, and catheter-based energy delivery, with efficacy varying by condition and patient selection. Cardiac sympathetic denervation (), particularly left cardiac sympathetic denervation (LCSD), is a established therapy for hereditary ventricular arrhythmias such as (LQTS) and (CPVT). It involves surgical resection of the lower half of the left and the first four thoracic ganglia, typically via (VATS) for reduced invasiveness. LCSD is indicated for patients refractory or intolerant to β-blockers, those at high risk of , or experiencing frequent (ICD) shocks. Seminal studies report a 91% reduction in cardiac events for LQTS and 92% for CPVT, with ICD shocks decreasing by 93-95%, though it is not curative and is often combined with ICD implantation. Safety is high, with transient in about 50% of cases and low rates of or infection. Bilateral CSD extends benefits to refractory ventricular tachyarrhythmias in structural heart disease, showing reduced arrhythmia burden in case series. Pulmonary artery denervation (PADN) emerges as a novel catheter-based intervention for pulmonary arterial hypertension (PAH), targeting perivascular sympathetic nerves to reduce pulmonary vascular resistance. Delivered via radiofrequency or ultrasound through the pulmonary arteries, PADN interrupts afferent and efferent neural fibers, lowering mean pulmonary artery pressure (mPAP) and improving hemodynamics. Clinical trials, including the PADN-1 study (n=66), demonstrate significant mPAP reduction (from 51±20 to 42±17 mmHg at 6 months) and enhanced 6-minute walk distance, with low procedural morbidity. A sham-controlled randomized trial (PADN-CFDA, n=128) confirmed benefits in WHO group 1 PAH, with improved exercise capacity and clinical outcomes at 6 months versus sham. As of 2025, PADN remains investigational, showing promise in medication-refractory cases but requiring larger trials against optimal medical therapy; in May 2025, the FDA granted breakthrough therapy designation to Gradient Embolics' PADN system. Radiofrequency (RF) denervation procedures address from facet joints, s, and peripheral nerves, commonly in unresponsive to conservative treatments. Continuous RF creates thermal lesions (80-90°C) on medial branch nerves supplying lumbar facets, providing targeted sensory interruption after confirmatory diagnostic blocks. Meta-analyses indicate moderate long-term pain relief (standardized mean difference -1.11 at 12 months versus sham) and functional improvements, though evidence quality varies. For pain, cooled RF produces larger lesions for durable relief up to 6 months in 50-70% of patients. Pulsed RF, avoiding tissue destruction, offers shorter-term for or . Guidelines recommend RF denervation for facetogenic pain following 70-80% relief from blocks, with risks including transient (5-10%) or motor weakness. These techniques prioritize precision via , enhancing outcomes in .

References

  1. [1]
    Medical Definition of Denervation - RxList
    Denervation: Loss of nerve supply. Causes of denervation include disease, chemical toxicity, physical injury, or intentional surgical interruption of a nerve.
  2. [2]
    Denervation - Oxford Reference
    n. interruption of the nerve supply to the muscles and skin. The muscle is paralysed and its normal tone (elasticity) is lost. The muscle fibres atrophy ...
  3. [3]
    Skeletal Muscle Denervation: Past, Present and Future - PMC - NIH
    Jul 6, 2022 · Denervation can be caused by numerous abnormalities: nerve injury due to trauma, nerve degeneration due to the loss of myelination, destruction of the NMJ.Missing: definition | Show results with:definition
  4. [4]
    Denervation - an overview | ScienceDirect Topics
    Denervation refers to the loss or interruption of nerve supply to tissues or organs, resulting in immediate paralysis of muscle. Unless only a single muscle is ...
  5. [5]
    Skeletal muscle denervation investigations: selecting an ... - NIH
    Denervation is a widely used experimental model to elucidate the mechanisms underlying muscle atrophy. Upon denervation, a loss of muscle mass is noted as early ...
  6. [6]
    Renal Denervation for the Treatment of Hypertension
    Aug 5, 2024 · In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, ...
  7. [7]
    Renal Denervation | Penn Medicine
    Renal denervation (also called renal ablation) is a minimally invasive, FDA-approved procedure to treat hypertension (high blood pressure)
  8. [8]
    Denervation - an overview | ScienceDirect Topics
    Denervation is defined as a medical procedure that interrupts specific afferent nerve fibers from the wrist joint to provide pain relief in patients with wrist ...
  9. [9]
    Signaling mechanisms regulating Wallerian degeneration - PMC
    Jun 5, 2014 · Wallerian degeneration (WD) occurs after an axon is cut or crushed and entails the disintegration and clearance of the severed axon distal ...
  10. [10]
    Wallerian degeneration: From mechanism to disease to imaging
    Jan 15, 2025 · Initial studies suggested that the formation mechanism of WD is related to the nutrition of neuronal cell bodies to axons.
  11. [11]
    Denervation changes in muscles | Radiology Reference Article
    Jul 30, 2025 · Denervation can be complete or partial, with partial denervation furtherly subdivided in regional or diffuse, reflecting in very heterogeneous ...
  12. [12]
    Key changes in denervated muscles and their impact on ... - NIH
    As compared to partial denervation, the Fib in complete denervation appears earlier, has larger amplitude, and has a shorter latency period (Desmedt and ...
  13. [13]
    Denervation - an overview | ScienceDirect Topics
    Denervation refers to the surgical procedure that involves the removal or disruption of nerves supplying a specific organ, such as the left ventricle, ...<|separator|>
  14. [14]
    Emergence of the Wallerian degeneration pathway as a mechanism ...
    Nov 16, 2020 · Augustus Volney Waller was a renowned British neurophysiologist who birthed the axon degeneration field in 1850 by describing curdling and ...
  15. [15]
    Degeneration and regeneration of the peripheral nervous system
    It is accompanied by a reprint of Augustus Waller's 1850 article, which gave rise to the pathologic process termed Wallerian degeneration. This review is ...Missing: studies | Show results with:studies
  16. [16]
    Splanchnicectomy for essential hypertension; results in 1266 cases
    Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953 Aug 15;152(16):1501-4. doi: 10.1001/jama.1953.03690160001001.
  17. [17]
    The Effects of Splanchnicectomy on the Blood Pressure in ...
    The effect of supradiaphragmatic splanchnicectomy on the blood pressure of 294 hypertensive patients followed for 10 to 18 months after surgery is compared ...Missing: introduction | Show results with:introduction
  18. [18]
    A History of the Development of Radiofrequency Neurotomy - PMC
    Dec 24, 2021 · Shealy was the first to use radiofrequency electrodes for denervation of the facet joints, introducing his technique in 1971. Several ...
  19. [19]
    A History of the Development of Radiofrequency Neurotomy - PubMed
    Dec 24, 2021 · Shealy was the first to use radiofrequency electrodes for denervation of the facet joints, introducing his technique in 1971. Several ...
  20. [20]
    Renal Denervation as a Therapeutic Approach for Hypertension
    Oct 12, 2009 · In this approach, renal sympathetic nerve ablation is achieved percutaneously via the lumen of the main renal artery using a catheter connected ...
  21. [21]
    2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC ...
    Aug 14, 2025 · The focus of this clinical practice guideline is to create a living, working document updating current knowledge in the field of high blood ...
  22. [22]
    Renal Denervation for Uncontrolled Hypertension - CMS
    The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively ...
  23. [23]
    Peripheral nerve injuries - Symptoms and causes - Mayo Clinic
    Mar 30, 2024 · Peripheral nerves can be damaged in several ways: Injury from an accident, a fall or sports can stretch, compress, crush or cut nerves. Medical ...
  24. [24]
    Acute Nerve Injury: Practice Essentials, Problem, Epidemiology
    Jun 13, 2021 · Trauma to peripheral nerves is relatively common. The most common injury is from blunt trauma or from penetrating missiles, such as bullets or ...
  25. [25]
    Acute Nerve Injury - StatPearls - NCBI Bookshelf - NIH
    The Seddon classification describes three categories of nerve injuries. The mildest form is a neurapraxic injury and results from focal ischemia or compression ...
  26. [26]
    Peripheral nerve injury grading simplified on MR neurography - NIH
    In 1943, Sir Herbert Seddon[4,5] described the three basic types of nerve injuries, and referred to them as neurapraxia, axonotmesis, and neurotmesis, using a ...
  27. [27]
    Peripheral Nerve Injury & Repair - Hand - Orthobullets
    Mar 18, 2025 · Seddon Classification ; Seddon Type. Myelin intact. Endoneurium intact. Wallerian Degeneration. Reversible ; Neuropraxia. No. Yes. No. Reversible.
  28. [28]
    Peripheral Nerve Trauma: Mechanisms of Injury and Recovery - PMC
    Crush injuries typically occur from an acute traumatic compression of the nerve from a blunt object, such as a bat, surgical clamp or other crushing object ...
  29. [29]
    Peripheral Nerve Injuries - Medscape Reference
    Oct 31, 2022 · Peripheral nerve injuries may result in loss of motor function, sensory function, or both. Such injuries may occur as a result of trauma ...
  30. [30]
    Epidemiology of brachial plexus injuries in a multitrauma population
    Brachial plexus injuries afflict slightly more than 1% of multitrauma victims. Motorcycle and snowmobile accidents carry especially high risks.
  31. [31]
    Brachial Plexus Injuries - StatPearls - NCBI Bookshelf - NIH
    Ballistic trauma is the second most common mechanism of injury to the brachial plexus and typically produces neuropraxia.[6] Injuries to the brachial plexus ...Etiology · Epidemiology · Evaluation · Treatment / Management
  32. [32]
    Peripheral Nerve Injury | Johns Hopkins Medicine
    Peripheral Nerve Injury Symptoms​​ People with traumatic nerve damage can experience severe, unrelenting pain, burning sensation, tingling or total loss of ...
  33. [33]
    Investigation of Ongoing Denervation and Reinnervation in ... - NIH
    Progressive motor neuron loss in ALS leads to denervation in muscle fibers. Reinnervation is achieved by collateral sprouting to compensate for denervated ...
  34. [34]
    Lower motor neuron involvement examined by quantitative ...
    Results: Denervation activity occurred in 72% of weak muscles but in only 45% of non-weak muscles. Fasciculations occurred in 56% of weak muscles and in 65% of ...
  35. [35]
    Clinical Overview of Poliomyelitis | Polio - CDC
    May 9, 2024 · Post-polio syndrome​​ The prevalence and incidence of PPS is unclear. Studies estimate that 25–40% of polio survivors suffer from PPS.
  36. [36]
    [PDF] Late effects of polio
    Jun 24, 2019 · After polio ongoing denervation and reinnervation occurs, but with time the ability to reinnervate orphaned fibres diminishes. This can ...
  37. [37]
    Conduction block and denervation in Guillain-Barré polyneuropathy
    We conclude that conduction block is the main cause of the acute paralysis and sensory loss in the GBS.
  38. [38]
    The Immunopathology of Multiple Sclerosis: An Overview - PMC
    This includes demyelination in the cortex and deep gray matter nuclei, as well as diffuse injury of the normal‐appearing white matter. The mechanisms ...Missing: denervation | Show results with:denervation
  39. [39]
    Diffusely abnormal white matter in multiple sclerosis
    Nov 9, 2021 · The hallmark feature of MS is the presence of focal lesions or plaques in the white matter of the CNS. ... The pathological characteristics of MS ...Missing: denervation | Show results with:denervation
  40. [40]
    Iatrogenic Nerve Injuries: Prevalence, Diagnosis and Treatment - PMC
    Iatrogenic nerve injuries can result from direct surgical trauma, mechanical stress on a nerve due to faulty positioning during anesthesia.
  41. [41]
    Sympathectomy | Johns Hopkins Medicine
    During a sympathectomy, a surgeon cuts or clamps a deep nerve that runs up and down along the spine. This prevents nerve signals from passing through it.
  42. [42]
    A systematic review and meta-analysis of T2, T3 or T4, to evaluate ...
    Mar 9, 2017 · We systematically reviewed and compared the clinical outcomes of thoracoscopic sympathectomy (TS) at different denervation levels for palmar hyperhidrosis.
  43. [43]
    Sacrifice of Involved Nerve Root during Surgical Resection of ... - NIH
    Jan 7, 2023 · The sacrifice of an involved nerve root in foraminal NSTs seems to represent a reasonable and relevant option to resect these tumors.
  44. [44]
    Radiofrequency Ablation (RFA): What It Is & Procedure
    When radiofrequency is applied to nerve tissue, it damages nerves, which prevents or stops the pain signal from reaching the brain and results in pain relief.
  45. [45]
    Bad back? Target pain with radiofrequency neurotomy. - Mayo Clinic
    Apr 6, 2024 · Radiofrequency neurotomy uses heat created by radio waves to target specific nerves. The treatment turns off the nerves' ability to send pain signals for a ...Overview · Why It's Done · What You Can Expect
  46. [46]
    Iatrogenic neurologic deficit after lumbar spine surgery: A review
    The average rate of reported neurologic complications within these papers was 9% (range 0.46–24%). Thirty patients of a total of 731 (4.1%) had a new onset ...
  47. [47]
    Radiofrequency Facet Denervation | Spine Center - OHSU
    Radiofrequency facet denervation is a minimally invasive procedure used to treat central neck or back pain caused by arthritis or injury to the facet joints.Missing: management | Show results with:management
  48. [48]
    Wallerian degeneration: the innate-immune response to traumatic ...
    Fragmentation of axons is first detected by light microscopy 36 to 44 hours after nerve transection in mice and rats (Figure 1C), but only after about one week ...
  49. [49]
    Chromatolysis: Do injured axons regenerate poorly when ...
    Specifically, CNS neurons undergoing chromatolysis (e.g., after spinal cord injury) show reduced levels of RNA in the nucleus and cytoplasm and reduced protein ...Missing: denervation | Show results with:denervation
  50. [50]
    Cortical plasticity and nerve regeneration after peripheral nerve injury
    Jan 7, 2021 · It has been suggested that cortical plasticity may be important for improving functional recovery after peripheral nerve damage.
  51. [51]
    Electrical Stimulation and improved outcomes for Brachial Plexus ...
    Feb 11, 2025 · Denervated muscles lose 50% of cross-sectional area within 3 months. Fibrosis and fatty infiltration render muscles nonfunctional by 2 years.Missing: timeline | Show results with:timeline
  52. [52]
    Effect of Delayed Peripheral Nerve Repair on Nerve Regeneration ...
    MG muscle at 3- and 6-months delay repair showed a significant decline in weight (61% and 27% compared with contra-lateral side). Muscle fiber atrophy and ...
  53. [53]
    Muscle Atrophy From Nerve Damage & Protein Synthesis
    Aug 31, 2018 · Muscle loss is a severe complication of many medical conditions such as cancer, cardiac failure, muscular dystrophies, and nerve damage.
  54. [54]
    The effect of denervation on the mechanical and electrical ... - NIH
    During the third and subsequent weeks, the contraction and relaxation phases of the twitches in all muscles became slower than normal. These changes were ...Missing: generation | Show results with:generation
  55. [55]
    Key changes in denervated muscles and their impact on...
    After denervation, individual muscle fiber cell membranes spontaneously depolarize creating an unstable resting membrane potential at the end-plate known as ...
  56. [56]
    The Biology of Long-Term Denervated Skeletal Muscle - PMC - NIH
    After denervation, muscle passes through three stages: 1) immediate loss of voluntary function and rapid loss of mass, 2) increasing atrophy and loss of ...
  57. [57]
    Complications with Peripheral Nerve Injury - Physiopedia
    Lacerations[edit | edit source] Laceration injuries are the second most common types of peripheral nerve injuries. ... crush injuries, nerve stretch injuries ...
  58. [58]
    Abnormal Reinnervation of Denervated Areas Following Nerve ...
    An injury to peripheral nerves leads to skin denervation, which often is followed by increased pain sensitivity of the denervated areas and the development ...
  59. [59]
    overactive bladder and detrusor underactivity - PMC - PubMed Central
    In lower urinary tract dysfunction, efferent control of the bladder can be impaired, for example due to peripheral “patchy” denervation. In this case, loss of ...
  60. [60]
    The effects of denervation, reinnervation, and muscle ... - PubMed
    Denervation-induced functional shortening of elbow flexor muscles leads to variable elbow flexion contractures depending on the degree, permanence, and ...Missing: complications | Show results with:complications
  61. [61]
    Optimizing the Timing of Peripheral Nerve Transfers for Functional ...
    Dec 13, 2021 · Irreversible muscle atrophy and fibrosis occurs within 12–18 months from denervation, defining the maximal time frame in which donor axons must ...Missing: timeline | Show results with:timeline
  62. [62]
    Functional recovery of severe obturator and femoral nerve injuries ...
    Feb 22, 2013 · With regard to upper-extremity nerve injury, muscle fibrosis and subsequent irreversible denervation have been suggested to occur 12–18 months ...Missing: timeline | Show results with:timeline
  63. [63]
    Pathophysiological significance of fasciculations in the early ...
    Some ALS patients with fatigue and mild weakness can have profuse fasciculations at an early phase in the evolution of the disease. Patients with denervation ...
  64. [64]
    MR Imaging in Two Cases of Subacute Denervation Change ... - NIH
    Damage to a lower motor nerve has profound effects on the muscle(s) it innervates, typically leading to flaccid paresis or paralysis and atrophy. The effects ...
  65. [65]
    Peripheral Neuropathy – Clinical and Electrophysiological ...
    As in AIDP, reflexes are usually absent or markedly attenuated, and examination reveals loss of large fiber sensory modalities (vibration and proprioception).
  66. [66]
    A Pilot Study Exploring the Role of A Series of Clinical Observational ...
    Aug 30, 2024 · This technology may prove helpful in detecting autonomic vasomotor and sudomotor changes seen after complete transection of a peripheral nerve.
  67. [67]
    Abnormal Spontaneous Electromyographic Activity - StatPearls - NCBI
    Sep 15, 2025 · Fibrillation potentials are spontaneous action potentials generated by individual muscle fibers in the absence of innervation. Firing patterns ...
  68. [68]
    History, Mechanisms and Clinical Value of Fibrillation Analyses in ...
    Fibrillation potentials are easily detected by electromyography (EMG) and, in general, are first detected within days to 1-4 weeks post denervation.
  69. [69]
    EMG: Myths and Facts - PMC - NIH
    The earliest manifestation of axonal denervation is the presence of positive sharp waves and fibrillation potentials. As noted earlier, it takes between 1 and 4 ...
  70. [70]
    MR Neurography and Quantitative Muscle MRI of Parsonage Turner ...
    Sep 13, 2023 · Given the propensity to only perform EMG at earliest 3 weeks following symptom onset to optimize the sensitivity of detecting denervation, EMG's ...Missing: specificity | Show results with:specificity
  71. [71]
    Nerve Conduction Studies and Electromyography - StatPearls - NCBI
    Feb 10, 2025 · EMG reveals signs of both active and chronic denervation across multiple body regions, including the tongue and upper and lower extremities. A ...
  72. [72]
    The role of high-resolution ultrasound and MRI in the evaluation of ...
    Nov 23, 2023 · Increased signal intensity on fluidsensitive sequences and thickening of the nerve can be seen as well as denervation edema and fatty atrophy ...
  73. [73]
    Peripheral Nerve Imaging - Musculoskeletal Diseases 2021-2024
    Apr 13, 2021 · MR imaging is more sensitive at detecting target muscle denervation oedema or atrophy than ultrasound. Diffuse muscle oedema and contrast ...<|separator|>
  74. [74]
    Magnetic Resonance Neurography: Improved Diagnosis of ...
    Dec 2, 2021 · While normal muscle tissue has an intermediate signal on T2w sequences, an increased T2w signal is the imaging correlate of muscle denervation ...
  75. [75]
    Quantitative muscle ultrasound is useful for evaluating secondary ...
    Sep 15, 2017 · After denervation, muscle tissues are replaced with fat and fibrous tissues, which can be detected as increased echo intensity (EI) and ...
  76. [76]
    Neuromuscular ultrasound in clinical practice: A review - PMC
    Neuromuscular ultrasound (NMUS) is becoming a standard element in the evaluation of peripheral nerve and muscle disease.
  77. [77]
    Diffusion tensor imaging in the musculoskeletal and peripheral ...
    Sep 30, 2017 · In this review, we describe the potential use of DTI to evaluate different musculoskeletal and peripheral nerve conditions, emphasising the ...
  78. [78]
    Visualizing axon regeneration after peripheral nerve injury ... - NIH
    Diffusion tensor imaging (DTI) with tractography is an MRI technique that can visualize nerve pathways by taking advantage of anisotropy of water diffusion ...
  79. [79]
    18F‐FDG uptake in denervated muscles of patients with peripheral ...
    This study revealed that denervated muscles in peripheral nerve lesions showed higher SUVs than healthy muscles in FDG‐PET, and it was associated with severity ...
  80. [80]
    PET imaging of oxidative metabolism abnormalities in ... - PubMed
    This study was designed to test the hypothesis that regional sympathetic denervation produces perfusion and metabolic alterations in myocardial tissue under ...
  81. [81]
    Peripheral Nerve Reconstruction after Injury: A Review of Clinical ...
    Recent surgical options including nerve transfers demonstrate promise in improving outcomes for proximal nerve injuries and experimental molecular and ...
  82. [82]
    Nerve Transfers for Traumatic Brachial Plexus Injury - NIH
    Nerve transfer is a procedure where an expendable nerve is connected to a more important nerve in order to reinnervate that nerve.
  83. [83]
    Timing of surgery in traumatic brachial plexus injury: a systematic ...
    Jun 1, 2018 · The results of this systematic review show that in stretch and blunt injury of the brachial plexus, the optimal time to surgery is shorter than 6 months.
  84. [84]
    The Role of Electrical Stimulation in Peripheral Nerve Regeneration
    Early studies of direct electrical stimulation of nerves demonstrated an overall positive effect, with greater axon sprouting, more rapid muscle reinnervation,
  85. [85]
    The use of electrical stimulation to enhance recovery following ...
    Sep 30, 2024 · The end result is upregulation of regeneration-associated genes in the neuronal body and accelerated transport to the axon front for regrowth.
  86. [86]
    Regenerative Medicine: A New Horizon in Peripheral Nerve Injury ...
    Mar 31, 2025 · Stem cells can differentiate into nerve cells and have paracrine and immunomodulatory effects. Its products, such as the secretome and exosome, ...
  87. [87]
    Skeletal muscle reprogramming enhances reinnervation after ...
    Oct 25, 2024 · The rate of human peripheral nerve regeneration is slow; approximately 1 inch per month. As a result, skeletal muscle fibers remain denervated ...
  88. [88]
    Treatment of Denervated Muscle Atrophy by Injectable Dual ... - NIH
    Feb 6, 2025 · In vivo studies using a rat model of nerve injury demonstrated that the EV‐loaded hydrogel (EVs@UR‐gel) significantly preserved muscle function.
  89. [89]
    Useful functional recovery and quality of life after surgical treatment ...
    Nerve repairs were followed by 58.33% of patients achieving M3+ recovery, while 41.66% recovered to the useful functional state (M4 or M5) With the use of TTs, ...
  90. [90]
    Renal denervation - CIRSE
    Renal denervation (RDN) is a minimally invasive procedure to treat resistant hypertension that has not responded to medication.
  91. [91]
    Renal Denervation - Division of Cardiology - UNC School of Medicine
    In this procedure, an interventional cardiologist uses a catheter (a thin plastic tube) to send ultrasound or radiofrequency (heat) energy to the renal arteries ...<|separator|>
  92. [92]
    Cover Story | Renal Denervation: Expanding Care For Treatment ...
    Aug 30, 2024 · RDN involves the selective disruption of the sympathetic nerves located in the renal arteries. By ablating these nerves, RDN aims to reduce ...<|control11|><|separator|>
  93. [93]
    Renal Denervation for Hypertension: A Systematic Review and Meta ...
    Dec 13, 2021 · The randomized placebo-controlled trials show consistently that renal denervation provides significant reduction in ambulatory and office blood pressure.
  94. [94]
    Renal Denervation After USA FDA Approval - PubMed Central - NIH
    As of 2025, regulatory approval has been granted in more than 60 countries, including the United States, marking a critical step towards its clinical ...
  95. [95]
    Effects of Catheter-Based Renal Denervation in Hypertension
    Oct 2, 2024 · Renal denervation exhibited no additional risk of vascular injury or renal function impairment.Clinical Perspective · Statistical Analysis · Safety Outcomes
  96. [96]
    Review and meta-analysis of renal artery damage following ...
    Renal artery injury following RF denervation could be caused by several mechanisms including physical trauma created by the guide catheter, denervation ...Missing: variability | Show results with:variability
  97. [97]
    Impact of Lesion Placement on Efficacy and Safety of Catheter ...
    Recently, variations in the distribution and density of the renal sympathetic nervous system, RDN's ultimate target, have been assessed in human tissue (18).
  98. [98]
    Radiofrequency techniques for chronic pain - PMC - NIH
    Radiofrequency (RF) techniques in chronic pain management are used to modulate sensory nerve transmission usually by producing thermal lesions.
  99. [99]
    Left cardiac sympathetic denervation: An important treatment option ...
    Left cardiac sympathetic denervation (LCSD) may reduce the wide gap between life-long ß-blocker medication and ICD implantation. Although LCSD is highly ...
  100. [100]
  101. [101]
  102. [102]
  103. [103]
    Current status of pulmonary artery denervation - PMC - NIH
    Oct 3, 2022 · PADN treatment has low mortality and morbidity and is associated with an improved 6-minute walking distance, a reduction in both mean pulmonary artery pressure.
  104. [104]
  105. [105]
  106. [106]
  107. [107]
    A Sham-Controlled Randomized PADN-CFDA Trial - PubMed
    Dec 12, 2022 · In patients with WHO group 1 PAH, PADN improved exercise capacity, hemodynamic status, and clinical outcomes during 6-month follow-up.
  108. [108]
    Comparative efficacy of radiofrequency denervation in chronic low ...
    Aug 5, 2022 · Fair evidence showed that RF-FC denervation was more effective for pain relief than sham control in the long term (SMD −1.11, 95% CI, −2.07 to − ...
  109. [109]
  110. [110]